Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(4 sites)
United States
Emory University, Atlanta, Georgia University of Michigan, Ann Arbor, Michigan University Hospital of Cleveland UH Seidman Cancer Center, Cleveland, Ohio University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, Oklahoma